NEW YORK, July 18, 2014 /PRNewswire/ -- Wolf Popper LLP is
investigating potential corporate malfeasance by the Board of
Directors of FedEx Corporation (NYSE: FDX), including whether the
Board has breached its fiduciary duties to its shareholders.
Shareholders of FedEx are urged to contact Fei-Lu Qian at 877.370.7703 or
fqian@wolfpopper.com.
On July 17, 2014, the Department
of Justice issued a 15-count indictment charging FedEx and related
entities with conspiracies to distribute controlled substances and
misbranded prescription drugs for their role in transporting
painkillers and other prescription drugs for illegal Internet
pharmacies. According to a press release issued by the DOJ in
connection with the indictment, as early as 2004, "FedEx knew that
it was delivering drugs to dealers and addicts" as FedEx's couriers
"expressed safety concerns that were circulated to FedEx Senior
management, including that FedEx trucks were stopped on the road by
online pharmacy customers demanding package of pills." In
response to these safety concerns, "FedEx adopted a procedure
whereby Internet pharmacy packages from problematic shippers were
held for pick up at specific stations, rather than delivered to the
recipient's address."
Wolf Popper LLP has extensive experience representing
shareholders in securities class actions and has successfully
recovered billions of dollars for defrauded investors. The
reputation and expertise of the firm in representing shareholders
has been repeatedly recognized by the courts, which have appointed
the firm to major positions in securities litigation. See
www.wolfpopper.com
Wolf Popper LLP
Fei-Lu Qian
845 Third Avenue
New York, NY 10022
Tel.: 877.370.7703
Fax: 877.370.7704
Email: fqian@wolfpopper.com
Attorney Advertising: Prior Results Do Not Guarantee A Similar
Outcome.
SOURCE Wolf Popper LLP